Naltrexone controlled release - Delpor
Alternative Names: DLP-160Latest Information Update: 28 Apr 2025
At a glance
- Originator Delpor
- Class Anti-inflammatories; Antineoplastics; Antivirals; Cyclopropanes; Drug withdrawal therapies; Ethers; Eye disorder therapies; Irritable bowel syndrome therapies; Ketones; Morphinans; Non-opioid analgesics; Small molecules
- Mechanism of Action Opioid receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Opioid-related disorders
Most Recent Events
- 28 Apr 2025 No recent reports of development identified for phase-I development in Opioid-related-disorders(Combination therapy, In volunteers, In adults) in Australia (SC, Implant)
- 07 Dec 2023 Delpor plans to file an IND application with the US FDA for Opioid-related disorders in early next year
- 07 Dec 2023 Delpor plans a phase Ib trial for Opioid-related disorders in the first half of 2024